AC Immune SA (NASDAQ: ACIU) and OncoMed Pharmaceuticals (NASDAQ:OMED) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations.

Earnings & Valuation

This table compares AC Immune SA and OncoMed Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
AC Immune SA $5.83 million 117.23 -$34.66 million N/A N/A
OncoMed Pharmaceuticals $24.55 million 6.79 -$82.33 million ($2.38) -1.86

AC Immune SA has higher revenue, but lower earnings than OncoMed Pharmaceuticals.

Profitability

This table compares AC Immune SA and OncoMed Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AC Immune SA N/A N/A N/A
OncoMed Pharmaceuticals -350.49% N/A -49.95%

Analyst Recommendations

This is a breakdown of recent ratings for AC Immune SA and OncoMed Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AC Immune SA 0 0 3 0 3.00
OncoMed Pharmaceuticals 0 6 2 0 2.25

AC Immune SA currently has a consensus target price of $21.67, indicating a potential upside of 80.86%. OncoMed Pharmaceuticals has a consensus target price of $6.00, indicating a potential upside of 35.44%. Given AC Immune SA’s stronger consensus rating and higher possible upside, analysts clearly believe AC Immune SA is more favorable than OncoMed Pharmaceuticals.

Institutional and Insider Ownership

18.1% of AC Immune SA shares are held by institutional investors. Comparatively, 51.7% of OncoMed Pharmaceuticals shares are held by institutional investors. 32.8% of OncoMed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

AC Immune SA beats OncoMed Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

About AC Immune SA

AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn, among others.

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.

Receive News & Ratings for AC Immune SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune SA and related companies with MarketBeat.com's FREE daily email newsletter.